BRAIN TUMOR LIBRARY
Glioblastoma | Treatment
48



Home > Brain tumor library > Diffuse astrocytic and oligodendroglial tumors > Glioblastoma > Treatment

CONTENTS





General overviews




Anjum K, Shagufta BI, Abbas SQ, Patel S, Khan I, Shah SAA, Akhter N, Hassan SSU.
Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review.
Biomed Pharmacother. 2017 Jun 2;92:681-689. doi: 10.1016/j.biopha.2017.05.125. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Morgan E, Mason W.
What are the prospects for combination therapy for glioblastoma?
Expert Rev Neurother. 2017 Jul 12:1-3. doi: 10.1080/14737175.2017.1351300. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Nam JY, de Groot JF.
Treatment of Glioblastoma.
J Oncol Pract. 2017 Oct;13(10):629-638. doi: 10.1200/JOP.2017.025536.
Source | Abstract | Full text | Similar articles



ANTIANGIOGENIC THERAPY



Popescu AM, Purcaru SO, Alexandru O, Dricu A.
New perspectives in glioblastoma antiangiogenic therapy.
Contemp Oncol (Pozn). 2016;20(2):109-18. doi: 10.5114/wo.2015.56122. Epub 2015 Dec 8.
Source | Abstract | Full text | Similar articles



BLOOD-BRAIN BARRIER



Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, Swanson KR, Kaufmann TJ, Brown PD, Agar NYR, Galanis E, Buckner JC, Elmquist WF.
Is the blood-brain barrier really disrupted in all glioblastomas? - A critical assessment of existing clinical data.
Neuro Oncol. 2017 Sep 7. doi: 10.1093/neuonc/nox175. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



CHEMOTHERAPY



Bastiancich C, Bastiat G, Lagarce F.
Gemcitabine and glioblastoma: challenges and current perspectives.
Drug Discov Today. 2017 Oct 23. pii: S1359-6446(17)30348-3. doi: 10.1016/j.drudis.2017.10.010. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Roberts NB, Wadajkar AS, Winkles JA, Davila E, Kim AJ, Woodworth GF.
Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma.
Oncoimmunology. 2016 Aug 19;5(9):e1208876.
Source | Abstract | Full text | Similar articles



COMBINED MODALITIES



Corso CD, Bindra RS.
Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions.
Semin Radiat Oncol. 2016 Oct;26(4):281-98. doi: 10.1016/j.semradonc.2016.06.003.
Source | Abstract | Full text | Similar articles



FOCUSED ULTRASOUND



Liu HL, Hsu PH, Lin CY, Huang CW, Chai WY, Chu PC, Huang CY, Chen PY, Yang LY, Kuo JS, Wei KC.
Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment.
Radiology. 2016 Oct;281(1):99-108. doi: 10.1148/radiol.2016152444. Epub 2016 May 18.
Source | Abstract | Full text | Similar articles



IMMUNOTHERAPY



Srinivasan VM, Ferguson SD, Lee S, Weathers SP, Kerrigan BCP, Heimberger AB.
Tumor Vaccines for Malignant Gliomas.
Neurotherapeutics. 2017 Apr;14(2):345-357. doi: 10.1007/s13311-017-0522-2.
Source | Abstract | Full text | Similar articles




Tsiatas M, Mountzios G, Curigliano G.
Future perspectives in cancer immunotherapy.
Ann Transl Med. 2016 Jul;4(14):273. doi: 10.21037/atm.2016.07.14.
Source | Abstract | Full text | Similar articles




Weller M, Roth P, Preusser M, Wick W, Reardon DA, Platten M, Sampson JH.
Vaccine-based immunotherapeutic approaches to gliomas and beyond.
Nat Rev Neurol. 2017 Jun;13(6):363-374. doi: 10.1038/nrneurol.2017.64. Epub 2017 May 12.
Source | Abstract | Full text | Similar articles



RADIOTHERAPY



Corso CD, Bindra RS, Mehta MP.
The role of radiation in treating glioblastoma: here to stay.
J Neurooncol. 2017 Mar 7. doi: 10.1007/s11060-016-2348-x. [Epub ahead of print]

Source | Abstract | Full text | Similar articles




Gzell C, Back M, Wheeler H, Bailey D, Foote M.
Radiotherapy in Glioblastoma: the Past, the Present and the Future.
Clin Oncol (R Coll Radiol). 2017 Jan;29(1):15-25. doi: 10.1016/j.clon.2016.09.015.
Source | Abstract | Full text | Similar articles




Howard SP, Krauze A, Chan MD, Tsien C, Tomé WA.
The evolving role for re-irradiation in the management of recurrent grade 4 glioma.
J Neurooncol. 2017 Apr 6. doi: 10.1007/s11060-017-2392-1. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Hofmaier J, Kantz S, Söhn M, Dohm OS, Bächle S, Alber M, Parodi K, Belka C, Niyazi M.
Hippocampal sparing radiotherapy for glioblastoma patients: a planning study using volumetric modulated arc therapy.
Radiat Oncol. 2016 Sep 8;11(1):118. doi: 10.1186/s13014-016-0695-6.
Source | Abstract | Full text | Similar articles



LASER INTERSTITIAL THERMAL THERAPY



Thomas JG, Rao G, Kew Y, Prabhu SS.
Laser interstitial thermal therapy for newly diagnosed and recurrent glioblastoma.
Neurosurg Focus. 2016 Oct;41(4):E12.
Source | Abstract | Full text | Similar articles



TUMOR-TREATING FIELDS



Akbarnejad Z, Eskandary H, Vergallo C, Nematollahi-Mahani SN, Dini L, Darvishzadeh-Mahani F, Ahmadi M.
Effects of extremely low-frequency pulsed electromagnetic fields (ELF-PEMFs) on glioblastoma cells (U87).
Electromagn Biol Med. 2016 Nov 22:1-10. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Burri SH, Gondi V, Brown PD, Mehta MP.
The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
Am J Clin Oncol. 2017 Aug 24. doi: 10.1097/COC.0000000000000395. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Davis ME.
Glioblastoma: Overview of Disease and Treatment.
Clin J Oncol Nurs. 2016 Oct 1;20(5):S2-8. doi: 10.1188/16.CJON.S1.2-8.
Source | Abstract | Full text | Similar articles




Hottinger AF, Pacheco P, Stupp R.
Tumor treating fields: a novel treatment modality and its use in brain tumors.
Neuro Oncol. 2016 Oct;18(10):1338-49. doi: 10.1093/neuonc/now182.
Source | Abstract | Full text | Similar articles




Korshoej AR, Saturnino GB, Rasmussen LK, von Oettingen G, Sørensen JC, Thielscher A.
Enhancing Predicted Efficacy of Tumor Treating Fields Therapy of Glioblastoma Using Targeted Surgical Craniectomy: A Computer Modeling Study.
PLoS One. 2016 Oct 3;11(10):e0164051. doi: 10.1371/journal.pone.0164051.
Source | Abstract | Full text | Similar articles




Li M, Song X, Zhu J, Fu A, Li J, Chen T.
The interventional effect of new drugs combined with the Stupp protocol on glioblastoma: A network meta-analysis.
Clin Neurol Neurosurg. 2017 May 11;159:6-12. doi: 10.1016/j.clineuro.2017.05.015. [Epub ahead of print]
Source | Abstract | Full AbstractAbstracttext | Similar articles




Mittal S, Klinger NV, Michelhaugh SK, Barger GR, Pannullo SC, Juhász C.
Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies.
J Neurosurg. 2017 Feb 24:1-8. doi: 10.3171/2016.9.JNS16452. [Epub ahead of print]

Source | Abstract | Full text | Similar articles




Mrugala MM, Ruzevick J, Zlomanczuk P, Lukas RV.
Tumor Treating Fields in Neuro-Oncological Practice.
Curr Oncol Rep. 2017 Aug;19(8):53. doi: 10.1007/s11912-017-0611-8.
Source | Abstract | Full text | Similar articles




Murphy J, Bowers ME, Barron L.
Optune®: Practical Nursing Applications.
Clin J Oncol Nurs. 2016 Oct 1;20(5):S14-9. doi: 10.1188/16.CJON.S1.14-19.
Source | Abstract | Full text | Similar articles




Sampson JH.
Alternating Electric Fields for the Treatment of Glioblastoma.
JAMA. 2015 Dec 15;314(23):2511-3. doi: 10.1001/jama.2015.16701.
Source | Abstract | Full text | Similar articles




Saria MG, Kesari S.
Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy.
Clin J Oncol Nurs. 2016 Oct 1;20(5):S9-S13. doi: 10.1188/16.CJON.S1.9-13.
Source | Abstract | Full text | Similar articles




Swanson KD, Lok E, Wong ET.
An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma.
Curr Neurol Neurosci Rep. 2016 Jan;16(1):8. doi: 10.1007/s11910-015-0606-5.
Source | Abstract | Full text | Similar articles




Schwartz MA, Onuselogu L.
Rationale and Background on Tumor-Treating Fields for Glioblastoma.
Clin J Oncol Nurs. 2016 Oct 1;20(5):S20-4. doi: 10.1188/16.CJON.S1.20-24.
Source | Abstract | Full text | Similar articles



ABOUT CLINICAL TRIALS



Grossman SA, Schreck KC, Ballman K, Alexander B.
Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma.
Neuro Oncol. 2017 Apr 1;19(4):469-474. doi: 10.1093/neuonc/nox030.
Source | Abstract | Full text | Similar articles




Wen PY, Jiang T, Schiff D.
How can we develop therapies for glioblastoma more efficiently? Randomized versus single-arm studies.
Neuro Oncol. 2017 Apr 1;19(4):459-460. doi: 10.1093/neuonc/nox041.
Source | Abstract | Full text | Similar articles



SPINAL CORD GLIOBLASTOMA



Behmanesh B, Setzer M, Konczalla J, Harter P, Quick-Weller J, Imoehl L, Franz K, Gessler F, Seifert V, Marquardt G.
Management of patients with primary intramedullary spinal cord glioblastoma.
World Neurosurg. 2016 Oct 21. pii: S1878-8750(16)31064-6. doi: 10.1016/j.wneu.2016.10.075. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





Laboratory investigations



CURCUMIN



Wang Y, Ying X, Xu H, Yan H, Li X, Tang H.
The functional curcumin liposomes induce apoptosis in C6 glioblastoma cells and C6 glioblastoma stem cells in vitro and in animals.
Int J Nanomedicine. 2017 Feb 17;12:1369-1384. doi: 10.2147/IJN.S124276.

Source | Abstract | Full text | Similar articles



GAMMA IRRADIATION



Nakajima H, Furukawa C, Chang YC, Ogata H, Magae J.
Delayed Growth Suppression and Radioresistance Induced by Long-Term Continuous Gamma Irradiation.
Radiat Res. 2017 Jun 9. doi: 10.1667/RR14666.1. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



IMMUNOTHERAPY



Alvarado AG, Thiagarajan PS, Mulkearns-Hubert EE, Silver DJ, Hale JS, Alban TJ, Turaga SM, Jarrar A, Reizes O, Longworth MS, Vogelbaum MA, Lathia JD.
Glioblastoma Cancer Stem Cells Evade Innate Immune Suppression of Self-Renewal through Reduced TLR4 Expression.
ell Stem Cell. 2017 Apr 6;20(4):450-461.e4. doi: 10.1016/j.stem.2016.12.001. Epub 2017 Jan 12.
Source | Abstract | Full text | Similar articles




Finocchiaro G.
TLRgeting Evasion of Immune Pathways in Glioblastoma.
Cell Stem Cell. 2017 Apr 6;20(4):422-424. doi: 10.1016/j.stem.2017.03.018.
Source | Abstract | Full text | Similar articles



METHYLATION



Ambady P, Wu YJ, Walker JM, Kersch C, Pagel MA, Woltjer RL, Fu R, Muldoon LL, Neuwelt EA.
Enhancing the cytotoxicity of chemoradiation with radiation-guided delivery of anti-MGMT morpholino oligonucleotides in non-methylated solid tumors.
Cancer Gene Ther. 2017 Jul 28. doi: 10.1038/cgt.2017.27. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



"NEURAL KILLER" CELLS



Bagó JR, Okolie O, Dumitru R, Ewend MG, Parker JS, Werff RV, Underhill TM, Schmid RS, Miller CR, Hingtgen SD.
Tumor-homing cytotoxic human induced neural stem cells for cancer therapy.
Sci Transl Med. 2017 Feb 1;9(375). pii: eaah6510. doi: 10.1126/scitranslmed.aah6510.
Source | Abstract | Full text | Similar articles




Mutukula N, Elkabetz Y.
"Neural Killer" Cells: Autologous Cytotoxic Neural Stem Cells for Fighting Glioma.
Cell Stem Cell. 2017 Apr 6;20(4):426-428. doi: 10.1016/j.stem.2017.03.019.
Source | Abstract | Full text | Similar articles



NOSE-TO-BRAIN DELIVERY



Sekerdag E, Lüle S, Bozdağ Pehlivan S, Öztürk N, Kara A, Kaffashi A, Vural I, Işıkay I, Yavuz B, Oguz KK, Söylemezoğlu F, Gürsoy-Özdemir Y, Mut M.
A potential non-invasive glioblastoma treatment: Nose-to-brain delivery of farnesylthiosalicylic acid incorporated hybrid nanoparticles.
J Control Release. 2017 Jul 3;261:187-198. doi: 10.1016/j.jconrel.2017.06.032. [Epub ahead of print] Accepted date: 2017 Jun 28.
Source | Abstract | Full text | Similar articles



REVERSING GLIOMA MALIGNANCY


ANTIDEPRESSANT DRUGS



Bielecka-Wajdman AM, Lesiak M, Ludyga T, Sieroń A, Obuchowicz E.
Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme.
Cancer Chemother Pharmacol. 2017 Jun;79(6):1249-1256. doi: 10.1007/s00280-017-3329-2. Epub 2017 May 12.
Source | Abstract | Full text | Similar articles



RESISTANCE



Stritzelberger J, Distel L, Buslei R, Fietkau R, Putz F.
Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.
Clin Transl Oncol. 2017 Aug 20. doi: 10.1007/s12094-017-1743-x. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



STATINS



Chang YL, Huang LC, Chen YC, Wang YW, Hueng DY, Huang SM.
The synergistic effects of valproic acid and fluvastatin on apoptosis induction in glioblastoma multiforme cell lines.
Int J Biochem Cell Biol. 2017 Oct 7;92:155-163. doi: 10.1016/j.biocel.2017.10.003. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Lu VM, McDonald KL.
The current evidence of statin use affecting glioblastoma prognosis.
J Clin Neurosci. 2017 May 8. pii: S0967-5868(16)31219-X. doi: 10.1016/j.jocn.2017.04.036. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Peng P, Wei W, Long C, Li J.
Atorvastatin augments temozolomide's efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling.
Biochem Biophys Res Commun. 2017 Jul 29;489(3):293-298. doi: 10.1016/j.bbrc.2017.05.147. Epub 2017 May 26.
Source | Abstract | Full text | Similar articles



SUBVENTRICULAR ZONE



Smith AW, Parashar B, Wernicke AG.
Subventricular zone-associated glioblastoma: A call for translational research to guide clinical decision making.
Neurogenesis (Austin). 2016 Aug 19;3(1):e1225548.
Source | Abstract | Full text | Similar articles



VALPROIC ACID



Chang YL, Huang LC, Chen YC, Wang YW, Hueng DY, Huang SM.
The synergistic effects of valproic acid and fluvastatin on apoptosis induction in glioblastoma multiforme cell lines.
Int J Biochem Cell Biol. 2017 Oct 7;92:155-163. doi: 10.1016/j.biocel.2017.10.003. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Hoja S, Schulze M, Rehli M, Proescholdt M, Herold-Mende C, Hau P, Riemenschneider MJ.
Molecular dissection of the valproic acid effects on glioma cells.
Oncotarget. 2016 Aug 18. doi: 10.18632/oncotarget.11379. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Tarasenko N, Chekroun-Setti H, Nudelman A, Rephaeli A.
Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
J Cell Biochem. 2017 Nov 14. doi: 10.1002/jcb.26512. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



Cancer cell metastasis is the main cause of patient deaths from solid tumors. While anticancer drugs are effective in destroying cancer cells, many of them fall short in blocking metastasis, which remains an unmet challenge [Wang and Huang, 2017]. Using two accepted methods to evaluate migration and invasion of cancer cells in vitro we have shown that VPA and AN446 at 100 fold lower doses were most effective in inhibiting migration and invasion.




Tseng JH, Chen CY, Chen PC, Hsiao SH, Fan CC, Liang YC, Chen CP.
Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression.
Oncotarget. 2017 Jan 18. doi: 10.18632/oncotarget.14716. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Zhang C, Liu S, Yuan X, Hu Z, Li H, Wu M, Yuan J, Zhao Z, Su J, Wang X, Liao Y, Liu Q.
Valproic Acid Promotes Human Glioma U87 Cells Apoptosis and Inhibits Glycogen Synthase Kinase-3β Through ERK/Akt Signaling.
Cell Physiol Biochem. 2016;39(6):2173-2185. Epub 2016 Nov 2
Source | Abstract | Full text | Similar articles





Clinical investigations


Newly diagnosed or recurrent tumors




Li G, Bonamici N, Dey M, Lesniak MS, Balyasnikova IV.
Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies.
Expert Opin Drug Deliv. 2017 Sep 18:1-10. doi: 10.1080/17425247.2018.1378642. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



BULKY GLIOBLASTOMA



Darmon I, Morisse MC, Coutte A, Blonski M, Rhun EL, Taillandier L, Roufai DB, Desenclos C, Trudel S, Faivre JC, Blanchard N, Chauffert B, Boone M.
Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment.
J Cancer. 2017 May 12;8(8):1417-1424. doi: 10.7150/jca.18339. eCollection 2017.
Source | Abstract | Full text | Similar articles



IMMUNOTHERAPY



Akasaki Y, Kikuchi T, Homma S, Koido S, Ohkusa T, Tasaki T, Hayashi K, Komita H, Watanabe N, Suzuki Y, Yamamoto Y, Mori R, Arai T, Tanaka T, Joki T, Yanagisawa T, Murayama Y.
Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma.
Cancer Immunol Immunother. 2016 Dec;65(12):1499-1509. Epub 2016 Sep 29.
Source | Abstract | Full text | Similar articles




Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, Kurien A, Priceman SJ, Wang X, Harshbarger TL, D'Apuzzo M, Ressler JA, Jensen MC, Barish ME, Chen M, Portnow J, Forman SJ, Badie B.
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.
N Engl J Med. 2016 Dec 29;375(26):2561-9. doi: 10.1056/NEJMoa1610497.
Source | Abstract | Full text | Similar articles




Kim WJ, Newman WC, Amankulor NM.
Phase I/II Trial of Combination of Temozolomide Chemotherapy and Immunotherapy With Fusions of Dendritic and Glioma Cells in Patients With Glioblastoma.
Comment on: Akasaki Y et al (2016), Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma.
Neurosurgery. 2017 Jul 1;81(1):N11. doi: 10.1093/neuros/nyx263.
Source | Abstract | Full text | Similar articles




Sidaway P.
Immunotherapy: Glioblastoma regression obtained with CAR T cells.
Nat Rev Clin Oncol. 2017 Jan 17. doi: 10.1038/nrclinonc.2017.2. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



PHARMACOTHERAPY



Franceschi E, Minichillo S, Brandes AA.
Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts.
CNS Drugs. 2017 Jul 5. doi: 10.1007/s40263-017-0454-8. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



RADIOTHERAPY



Achari R, Arunsingh M, Badgami RK, Saha A, Chatterjee S, Shrimali RK, Mallick I, Arun B.
High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma.
Clin Oncol (R Coll Radiol). 2017 Feb 8. pii: S0936-6555(17)30036-5. doi: 10.1016/j.clon.2017.01.010. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Pinel B, Duchesne M, Godet J, Milin S, Berger A, Wager M, Karayan-Tapon L.
Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide.
J Neurooncol. 2017 Jan 10. doi: 10.1007/s11060-016-2367-7. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



SURGERY



Shonka NA, Aizenberg MR.
Extent of Resection in Glioblastoma.
J Oncol Pract. 2017 Oct;13(10):641-642. doi: 10.1200/JOP.2017.027599.
Source | Abstract | Full text | Similar articles



Newly diagnosed tumors



OVERVIEWS



Mallick S, Gandhi AK, Rath GK.
Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future direction.
Indian J Med Paediatr Oncol. 2015 Oct-Dec;36(4):229-37. doi: 10.4103/0971-5851.171543.
Source | Abstract | Full text | Similar articles



ANTI-EGFR MAB



Reardon DA, Lassman AB, van den Bent M, Kumthekar P, Merrell R, Scott AM, Fichtel L, Sulman EP, Gomez E, Fischer J, Lee HJ, Munasinghe W, Xiong H, Mandich H, Roberts-Rapp L, Ansell P, Holen KD, Gan HK.
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Neuro Oncol. 2016 Dec 29. pii: now257. doi: 10.1093/neuonc/now257. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



ANTI-ANGIOGENIC THERAPY



Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP.
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
N Engl J Med. 2014 Feb 20;370(8):699-708. doi: 10.1056/NEJMoa1308573.
Source | Abstract | Full text | Similar articles




Fu P, He YS, Huang Q, Ding T, Cen YC, Zhao HY, Wei X.
Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials.
Mol Clin Oncol. 2016 May;4(5):833-838. Epub 2016 Mar 10.
Source | Abstract | Full text | Similar articles




Hata N, Yoshimoto K, Hatae R, Kuga D, Akagi Y, Sangatsuda Y, Suzuki SO, Shono T, Mizoguchi M, Iihara K.
Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status.
Onco Targets Ther. 2017 Jan 18;10:429-437. doi: 10.2147/OTT.S125587. eCollection 2017.
Source | Abstract | Full text | Similar articles



TEMOZOLOMIDE



Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T.
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
N Engl J Med. 2014 Feb 20;370(8):709-22. doi: 10.1056/NEJMoa1308345.
Source | Abstract | Full text | Similar articles




Nowosielski M, Ellingson BM, Chinot OL, Garcia J, Revil C, Radbruch A, Nishikawa R, Mason WP, Henriksson R, Saran F, Kickingereder P, Platten M, Sandmann T, Abrey LE, Cloughesy TF, Bendszus M, Wick W.
Radiologic progression of glioblastoma under therapy - an exploratory analysis of AVAglio.
Neuro Oncol. 2017 Sep 1. doi: 10.1093/neuonc/nox162. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Rutledge MR, Waddell JA, Solimando DA Jr.
Bevacizumab and Temozolomide Plus Radiation Regimen for Glioblastoma Multiforme.
Hosp Pharm. 2015 Sep;50(8):672-7. doi: 10.1310/hpj5008-672. Epub 2015 Sep 16.
Source | Abstract | Full text | Similar articles




Saran F, Chinot OL, Henriksson R, Mason W, Wick W, Cloughesy T, Dhar S, Pozzi E, Garcia J, Nishikawa R.
Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.
Neuro Oncol. 2016 Jul;18(7):991-1001. doi: 10.1093/neuonc/nov300. Epub 2016 Jan 24.
Source | Abstract | Full text | Similar articles



CHEMOTHERAPY



Bhandari M, Gandhi AK, Devnani B, Kumar P, Sharma DN, Julka PK.
Comparative Study of Adjuvant Temozolomide Six Cycles Versus Extended 12 Cycles in Newly Diagnosed Glioblastoma Multiforme.
J Clin Diagn Res. 2017 May;11(5):XC04-XC08. doi: 10.7860/JCDR/2017/27611.9945. Epub 2017 May 1.
Source | Abstract | Full text | Similar articles




Feng E, Sui C, Wang T, Sun G.
Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis.
Eur Neurol. 2017;77(3-4):201-210. doi: 10.1159/000455842. Epub 2017 Feb 14.
Source | Abstract | Full text | Similar articles



EXTENDED ADJUVANT TEMOZOLOMIDE BEYOND SIX CYCLES


***

Hsieh SY, Chan DT, Kam MK, Loong HH, Tsang WK, Poon DM, Ng SC, Poon WS.
Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma.
Hong Kong Med J. 2017 Aug 11. doi: 10.12809/hkmj165002. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



ELDERLY PATIENTS



Hutchinson L.
CNS cancer: New chemoradiation standard for elderly patients with glioblastoma.
Nat Rev Clin Oncol. 2017 Apr 11. doi: 10.1038/nrclinonc.2017.54. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



**

Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP; Trial Investigators.
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
N Engl J Med. 2017 Mar 16;376(11):1027-1037. doi: 10.1056/NEJMoa1611977.
Source | Abstract | Full text | Similar articles



EVEROLIMUS



Chinnaiyan P, Won M, Wen PY, Rojiani AM, Werner-Wasik M, Shih HA, Ashby LS, Yu HM, Stieber VW, Malone SC, Fiveash JB, Mohile NA, Ahluwalia MS, Wendland MM, Stella PJ, Kee AY, Mehta MP.
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: Results of NRG Oncology RTOG 0913.
Neuro Oncol. 2017 Nov 6. doi: 10.1093/neuonc/nox209. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



GLIADEL WAFERS



Ashby LS, Smith KA, Stea B.
Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
World J Surg Oncol. 2016 Aug 24;14(1):225. doi: 10.1186/s12957-016-0975-5.
Source | Abstract | Full text | Similar articles



IMMUNOTHERAPY


***

Batich KA, Reap EA, Archer GE, Sanchez-Perez L, Nair SK, Schmittling RJ, Norberg P, Xie W, Herndon JE 2nd, Healy P, McLendon RE, Friedman AH, Friedman HS, Bigner D, Vlahovic G, Mitchell DA, Sampson JH.
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
Clin Cancer Res. 2017 Apr 15;23(8):1898-1909. doi: 10.1158/1078-0432.CCR-16-2057.
Source | Abstract | Full text | Similar articles




Kong DS, Nam DH, Kang SH, Lee JW, Chang JH, Kim JH, Lim YJ, Koh YC, Chung YG, Kim JM, Kim CH.
Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in korea.
Oncotarget. 2016 Sep 27. doi: 10.18632/oncotarget.12273. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



INIBITION OF VASCULOGENESIS



Rios A, Hsu SH, Blanco A, Buryanek J, Day AL, McGuire MF, Brown RE.
Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide.
Oncoscience. 2016 Jun 11;3(5-6):156-63. doi: 10.18632/oncoscience.311. eCollection 2016.
Source | Abstract | Full text | Similar articles



INTRAOPERATIVE RADIOTHERAPY



Giordano FA, Wenz F, Petrecca K.
Rationale for intraoperative radiotherapy (IORT) in glioblastoma.
J Neurosurg Sci. 2016 Jan 29. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



PSEUDOPROGRESSION



Balaña C, Capellades J, Pineda E, Estival A, Puig J, Domenech S, Verger E, Pujol T, Martinez-García M, Oleaga L, Velarde J, Mesia C, Fuentes R, Marruecos J, Del Barco S, Villà S, Carrato C, Gallego O, Gil-Gil M, Craven-Bartle J, Alameda F; GLIOCAT Group.
Pseudoprogression as an adverse event of glioblastoma therapy.
Cancer Med. 2017 Nov 3. doi: 10.1002/cam4.1242. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



PROTON BEAM THERAPY



Mizumoto M, Yamamoto T, Ishikawa E, Matsuda M, Takano S, Ishikawa H, Okumura T, Sakurai H, Matsumura A, Tsuboi K.
Proton beam therapy with concurrent chemotherapy for glioblastoma multiforme: comparison of nimustine hydrochloride and temozolomide.
J Neurooncol. 2016 Aug 17. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



RADIOCHEMOTHERAPY



Blumenthal DT, Gorlia T, Gilbert MR, Kim MM, Burt Nabors L, Mason WP, Hegi ME, Zhang P, Golfinopoulos V, Perry JR, Hyun Nam D, Erridge SC, Corn BW, Mirimanoff RO, Brown PD, Baumert BG, Mehta MP, van den Bent MJ, Reardon DA, Weller M, Stupp R.
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
Neuro Oncol. 2017 Mar 24. doi: 10.1093/neuonc/nox025. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Choi SH, Kim JW, Chang JS, Cho JH, Kim SH, Chang JH, Suh CO.
Impact of Including Peritumoral Edema in Radiotherapy Target Volume on Patterns of Failure in Glioblastoma following Temozolomide-based Chemoradiotherapy.
Sci Rep. 2017 Feb 8;7:42148. doi: 10.1038/srep42148.
Source | Abstract | Full text | Similar articles




Fariselli L, Cuppini L, Gaviani P, Marchetti M, Pinzi V, Milanesi I, Simonetti G, Tramacere I, DiMeco F, Salmaggi A, Silvani A.
Short course radiotherapy concomitant with temozolomide in GBM patients: a phase II study.
Tumori. 2017 Jul 8:0. doi: 10.5301/tj.5000672. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Gramatzki D, Kickingereder P, Hentschel B, Felsberg J, Herrlinger U, Schackert G, Tonn JC, Westphal M, Sabel M, Schlegel U, Wick W, Pietsch T, Reifenberger G, Loeffler M, Bendszus M, Weller M.
Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Neurology. 2017 Mar 15. pii: 10.1212/WNL.0000000000003809. doi: 10.1212/WNL.0000000000003809. [Epub ahead of print]

Source | Abstract | Full text | Similar articles




Grossman SA, Kleinberg L.
A search for the "Goldilocks zone" with regard to the optimal duration of adjuvant temozolomide in patients with glioblastoma.
Neuro Oncol. 2017 Aug 1;19(8):1019-1020. doi: 10.1093/neuonc/nox046.
Comment on: Blumenthal DT et al., Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
Source | Abstract | Full text | Similar articles




Haque W, Verma V, Butler EB, Teh BS.
Definitive chemoradiation at high volume facilities is associated with improved survival in glioblastoma.
J Neurooncol. 2017 Jul 7. doi: 10.1007/s11060-017-2563-0. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Jayamanne D, Wheeler H, Cook R, Teo C, Brazier D, Schembri G, Kastelan M, Guo L, Back MF.
Survival improvements with adjuvant therapy in patients with glioblastoma.
ANZ J Surg. 2017 Sep 18. doi: 10.1111/ans.14153. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Malmström A, Poulsen HS, Grønberg BH, Stragliotto G, Hansen S, Asklund T, Holmlund B, Łysiak M, Dowsett J, Kristensen BW, Söderkvist P, Rosell J, Henriksson R; Nordic Clinical Brain Tumor Study Group (NCBTSG).
Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
Acta Oncol. 2017 Jul 4:1-10. doi: 10.1080/0284186X.2017.1332780. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Nachbichler SB, Schupp G, Ballhausen H, Niyazi M, Belka C.
Temozolomide during radiotherapy of glioblastoma multiforme : Daily administration improves survival.
Strahlenther Onkol. 2017 Feb 14. doi: 10.1007/s00066-017-1110-4. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Salma S, Djan I, Bjelan M, Vulekovic P, Novakovic M, Vidovic V, Lucic M.
Benefit and outcome of using temozolomide-based chemoradiotherapy followed by temozolomide alone for glioblastoma in clinical practice.
J BUON. 2017 Sep-Oct;22(5):1233-1239.
Source | Abstract | Full text | Similar articles




Scoccianti S, Krengli M, Marrazzo L, Magrini SM, Detti B, Fusco V, Pirtoli L, Doino D, Fiorentino A, Masini L, Greto D, Buglione M, Rubino G, Lonardi F, Migliaccio F, Marzano S, Santoni R, Ricardi U, Livi L.
Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).
Radiol Med. 2017 Sep 6. doi: 10.1007/s11547-017-0806-y. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Skardelly M, Dangel E, Gohde J, Noell S, Behling F, Lepski G, Borchers C, Koch M, Schittenhelm J, Bisdas S, Naumann A, Paulsen F, Zips D, von Hehn U, Ritz R, Tatagiba MS, Tabatabai G.
Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma.
Oncologist. 2017 Mar 30. pii: theoncologist.2016-0347. doi: 10.1634/theoncologist.2016-0347. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



RADIOSURGERY



Azoulay M, Ho CK, Fujimoto DK, Modlin LA, Gibbs IC, Hancock SL, Li G, Chang SD, Adler JR Jr, Harsh GR, Nagpal S, Thomas R, Recht L, Choi CY, Soltys SG.
A Phase I/II Trial of 5 Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma Multiforme.
Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E131-E132. doi: 10.1016/j.ijrobp.2016.06.921.
Source | Abstract | Full text | Similar articles



TUMOR-TREATING FIELDS



Majd P, O'Connell DE, Kim RC, Bota DA, Carrillo JA.
Case of glioblastoma patient treated with tumor treating fields therapy at recurrence degenerating to sarcoma.
CNS Oncol. 2017 Mar 17. doi: 10.2217/cns-2016-0035. [Epub ahead of print]

Source | Abstract | Full text | Similar articles




O'Connell D, Shen V, Loudon W, Bota DA.
First report of tumor treating fields use in combination with bevacizumab in a pediatric patient: a case report.
CNS Oncol. 2017 Jan;6(1):11-18. doi: 10.2217/cns-2016-0018. Epub 2016 Dec 5.
Source | Abstract | Full text | Similar articles




Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z.
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669.
Source | Abstract | Full text | Similar articles




Zhu JJ, Demireva P, Kanner AA, Pannullo S, Mehdorn M, Avgeropoulos N, Salmaggi A, Silvani A, Goldlust S, David C, Benouaich-Amiel A; Zvi Ram on behalf of the EF-14 Trial Investigators.
Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
J Neurooncol. 2017 Aug 28. doi: 10.1007/s11060-017-2601-y. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



UNRESECTABLE TUMOR



Brehmer S, Guthier CV, Clausen S, Schneider F, Schulte DM, Benker M, Bludau F, Glatting G, Marx A, Schmiedek P, Hesser J, Wenz F, Giordano FA.
Combined stereotactic biopsy and stepping-source interstitial irradiation of unresectable glioblastoma multiforme.
J Neurosurg Sci. 2016 Jan 15. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





Recurrent tumors



OVERVIEWS



Kamiya-Matsuoka C, Gilbert MR.
Treating recurrent glioblastoma: an update.
CNS Oncol. 2015 March;4(2):91-104. doi: 10.2217/cns.14.55.
Source | Abstract | Full text | Similar articles




Osuka S, Van Meir EG.
Overcoming therapeutic resistance in glioblastoma: the way forward.
J Clin Invest. 2017 Feb 1;127(2):415-426. doi: 10.1172/JCI89587. Epub 2017 Feb 1.
Source | Abstract | Full text | Similar articles




Rapp M, Baernreuther J, Turowski B, Steiger HJ, Sabel M, Kamp MA.
Recurrence pattern analysis of primary glioblastoma.
World Neurosurg. 2017 Apr 18. pii: S1878-8750(17)30548-X. doi: 10.1016/j.wneu.2017.04.053. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Roy S, Lahiri D, Maji T, Biswas J.
Recurrent Glioblastoma: Where we stand.
South Asian J Cancer. 2015 Oct-Dec;4(4):163-73. doi: 10.4103/2278-330X.175953.
Source | Abstract | Full text | Similar articles




Tosoni A, Franceschi E, Poggi R, Brandes AA.
Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences.
Curr Treat Options Oncol. 2016 Sep;17(9):49. doi: 10.1007/s11864-016-0422-4.
Source | Abstract | Full text | Similar articles



ELDERLY PATIENTS



Zanello M, Roux A, Ursu R, Peeters S, Bauchet L, Noel G, Guyotat J, Le Reste PJ, Faillot T, Litre F, Desse N, Emery E, Petit A, Peltier J, Voirin J, Caire F, Barat JL, Vignes JR, Menei P, Langlois O, Dezamis E, Carpentier A, Dam Hieu P, Metellus P, Pallud J; On the Behalf of the Club de Neuro-Oncologie of the Société Française de Neurochirurgie.
Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment?
J Neurooncol. 2017 Jul 19. doi: 10.1007/s11060-017-2573-y. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



DECISION MAKING



Shi W, Scannell Bryan M, Gilbert MR, Mehta MP, Blumenthal DT, Brown PD, Valeinis E, Hopkins K, Souhami L, Andrews DW, Tzuk-Shina T, Howard SP, Youssef EF, Lessard N, Dignam JJ, Werner-Wasik M.
Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.
Int J Radiat Oncol Biol Phys. 2017 Sep 4. pii: S0360-3016(17)33835-X. doi: 10.1016/j.ijrobp.2017.08.038. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Zussman BM, Engh JA.
Patterns of Care and Clinical Decision Making for Recurrent Glioblastoma Multiforme.
Neurosurgery. 2016 Feb;78(2):N12-4. doi: 10.1227/01.neu.0000479889.72124.20.
Source | Abstract | Full text | Similar articles



5-ALA AND IMRI



Quick-Weller J, Lescher S, Forster MT, Konczalla J, Seifert V, Senft C.
Combination of 5-ALA and iMRI in re-resection of recurrent glioblastoma.
Br J Neurosurg. 2016 Jun;30(3):313-7. doi: 10.3109/02688697.2015.1119242. Epub 2016 Jan 8.
Source | Abstract | Full text | Similar articles



ANTI-ANGIOGENIC THERAPY


BEVACIZUMAB



Blumenthal DT, Mendel L, Bokstein F.
The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?
J Neurooncol. 2016 May;127(3):493-502. doi: 10.1007/s11060-015-2025-5. Epub 2015 Dec 31. Erratum in:
J Neurooncol. 2016 May;127(3):503.
Source | Abstract | Full text | Similar articles




Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot OL, Balana C, Macdonald DR, Westphal M, Hopkins K, Weller M, Bais C, Sandmann T, Bruey JM, Koeppen H, Liu B, Verret W, Phan SC, Shames DS.
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.
J Clin Oncol. 2017 Jan 20;35(3):343-351. doi: 10.1200/JCO.2015.64.7685. Epub 2016 Dec 5.
Source | Abstract | Full text | Similar articles




Erdem-Eraslan L, van den Bent MJ, Hoogstrate Y, Naz-Khan H, Stubbs A, van der Spek P, Böttcher R, Gao Y, de Wit M, Taal W, Oosterkamp HM, Walenkamp A, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, van der Holt B, Vernhout RM, Sillevis Smitt PA, Kros JM, French PJ.
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.
Cancer Res. 2016 Feb 1;76(3):525-34. doi: 10.1158/0008-5472.CAN-15-0776. Epub 2016 Jan 13.
Source | Abstract | Full text | Similar articles




Ghiaseddin A, Reardon D, Massey W, Mannerino A, Lipp ES, Herndon JE 2nd, McSherry F, Desjardins A, Randazzo D, Friedman HS, Peters KB.
Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.
Oncologist. 2017 Nov 13. pii: theoncologist.2017-0501. doi: 10.1634/theoncologist.2017-0501. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Gilbert MR, Pugh SL, Aldape K, Sorensen AG, Mikkelsen T, Penas-Prado M, Bokstein F, Kwok Y, Lee RJ, Mehta M.
NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.
J Neurooncol. 2016 Oct 21. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




McCracken DJ, Celano EC, Voloschin AD, Read WL, Olson JJ.
Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma.
J Neurooncol. 2016 Aug 9. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WK, de Groot JF.
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
J Neurooncol. 2016 Jul 12. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



BEVACIZUMAB AND VALGANCICLOVIR



Peng C, Wang J, Tanksley JP, Mobley BC, Ayers GD, Moots PL, Clark SW.
Valganciclovir and bevacizumab for recurrent glioblastoma: A single-institution experience.
Mol Clin Oncol. 2016 Feb;4(2):154-158. Epub 2015 Dec 4.
Source | Abstract | Full text | Similar articles



THALIDOMIDE



Surasak Phuphanich
Recurrent Multicentric Glioblastoma Multiforme Responds to Thalidomide and Chemotherapy
Oncology (Williston Park). 2002 Mar 1;16(3):276, 278.
Source | Abstract | Full text | Similar articles



CHEMOTHERAPY


DOXORUBICIN



Sardi I.
Prolonged exposure to doxorubicin after radiotherapy in glioblastoma.
Future Oncol. 2016 Mar;12(5):581-3. doi: 10.2217/fon.15.354. Epub 2016 Jan 22.
Source | Abstract | Full text | Similar articles



IRINOTECAN



Clarke JL, Molinaro AM, Cabrera JR, DeSilva AA, Rabbitt JE, Prey J, Drummond DC, Kim J, Noble C, Fitzgerald JB, Chang SM, Butowski NA, Taylor JW, Park JW, Prados MD.
A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.
Cancer Chemother Pharmacol. 2017 Mar;79(3):603-610. doi: 10.1007/s00280-017-3247-3. Epub 2017 Feb 23.
Source | Abstract | Full text | Similar articles



TEMOZOLOMIDE



Badruddoja MA, Pazzi M, Sanan A, Schroeder K, Kuzma K, Norton T, Scully T, Mahadevan D, Ahmadi MM.
Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
Cancer Chemother Pharmacol. 2017 Aug 14. doi: 10.1007/s00280-017-3405-7. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Kim C, Kim HS, Shim WH, Choi CG, Kim SJ, Kim JH.
Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence.
Radiology. 2016 Jul 18:152152. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Wang Y, Kong X, Guo Y, Wang R, Ma W.
Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients.
Medicine (Baltimore). 2017 Mar;96(10):e6261. doi: 10.1097/MD.0000000000006261. Epub 2017 Mar 10.

Source | Abstract | Full text | Similar articles



EGFR INHIBITORS



Sepúlveda-Sánchez JM, Vaz MÁ, Balañá C, Gil-Gil M, Reynés G, Gallego Ó, Martínez-García M, Vicente E, Quindós M, Luque R, Ramos A, Ruano Y, Pérez-Segura P, Benavides M, Sánchez-Gómez P, Hernández-Laín A.
Phase II trial of dacomitinib, a pan-HER (human epidermal growth factor receptor) tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
Neuro Oncol. 2017 Jun 1. doi: 10.1093/neuonc/nox105. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



GENE THERAPY



Wang W, Liu F, Xiang B, Xiang C, Mou X.
Stem cells as cellular vehicles for gene therapy against glioblastoma.
Int J Clin Exp Med. 2015 Oct 15;8(10):17102-9. eCollection 2015.
Source | Abstract | Full text | Similar articles



IGF-1 RECEPTOR INHIBITORS



Aiken R, Axelson M, Harmenberg J, Klockare M, Larsson O, Wassberg C.
Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response.
Oncotarget. 2017 Sep 6;8(46):81501-81510. doi: 10.18632/oncotarget.20662. eCollection 2017 Oct 6.
Source | Abstract | Full text | Similar articles



INTEGRIN RECEPTOR ANTAGONIST



Cirkel GA, Kerklaan BM, Vanhoutte F, der Aa AV, Lorenzon G, Namour F, Pujuguet P, Darquenne S, de Vos FY, Snijders TJ, Voest EE, Schellens JH, Lolkema MP.
A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies.
Invest New Drugs. 2016 Apr;34(2):184-92. doi: 10.1007/s10637-015-0320-9. Epub 2016 Jan 20.
Source | Abstract | Full text | Similar articles



p53-INDEPENDENT APOPTOSIS



Arrillaga-Romany I, Chi AS, Allen JE, Oster W, Wen PY, Batchelor TT.
A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.
Oncotarget. 2017 May 12;8(45):79298-79304. doi: 10.18632/oncotarget.17837. eCollection 2017 Oct 3.
Source | Abstract | Full text | Similar articles



PDGFR INHIBITORS


MEDI-575



Phuphanich S, Raizer J, Chamberlain M, Canelos P, Narwal R, Hong S, Miday R, Nade M, Laubscher K.
Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma.
J Neurooncol. 2017 Jan;131(1):185-191. doi: 10.1007/s11060-016-2287-6.
Source | Abstract | Full text | Similar articles



PDGFR PLUS VEGFR INHIBITORS


SUNITINIB



Grisanti S, Ferrari VD, Buglione M, Agazzi GM, Liserre R, Poliani L, Buttolo L, Gipponi S, Pedersini R, Consoli F, Panciani P, Roca E, Spena G, Triggiani L, Berruti A; Gruppo Neuro-Oncologico Bresciano
Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature.
J Neurosurg Sci. 2016 Sep 28. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



RADIOSURGERY



Abbassy M, Missios S, Barnett GH, Brewer C, Peereboom DM, Ahluwalia M, Neyman G, Chao ST, Suh JH, Vogelbaum MA.
Phase I Trial of Radiosurgery Dose Escalation Plus Bevacizumab in Patients With Recurrent/Progressive Glioblastoma.
Neurosurgery. 2017 Jul 21. doi: 10.1093/neuros/nyx369. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Holt DE, Bernard ME, Quan K, Clump DA, Engh JA, Burton SA, Heron DE.
Salvage stereotactic radiosurgery for recurrent glioblastoma multiforme with prior radiation therapy.
J Cancer Res Ther. 2016 Oct-Dec;12(4):1243-1248. doi: 10.4103/0973-1482.199537.
Source | Abstract | Full text | Similar articles




Frischer JM, Marosi C, Woehrer A, Hainfellner JA, Dieckmann KU, Eiter H, Wang WT, Mallouhi A, Ertl A, Knosp E, Filipits M, Kitz K, Gatterbauer B.
Gamma Knife Radiosurgery in Recurrent Glioblastoma.
Stereotact Funct Neurosurg. 2016;94(4):265-272. Epub 2016 Oct 8.
Source | Abstract | Full text | Similar articles




Redmond KJ, Mehta M.
Stereotactic Radiosurgery for Glioblastoma.
Cureus. 2015 Dec 17;7(12):e413. doi: 10.7759/cureus.413.
Source | Abstract | Full text | Similar articles



SECOND RADIOTHERAPY



Barney C, Shukla G, Bhamidipati D, Palmer JD.
Re-irradiation for recurrent glioblastoma multiforme.
Chin Clin Oncol. 2017 Aug;6(4):36. doi: 10.21037/cco.2017.06.18.
Source | Abstract | Full text | Similar articles




Schnell O, Thorsteinsdottir J, Fleischmann DF, Lenski M, Abenhardt W, Giese A, Tonn JC, Belka C, Kreth FW, Niyazi M.
Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma.
J Neurooncol. 2016 Dec;130(3):591-599. Epub 2016 Sep 6.
Source | Abstract | Full text | Similar articles




Straube C, Elpula G, Gempt J, Gerhardt J, Bette S, Zimmer C, Schmidt-Graf F, Meyer B, Combs SE.
Re-irradiation after gross total resection of recurrent glioblastoma : Spatial pattern of recurrence and a review of the literature as a basis for target volume definition.
Strahlenther Onkol. 2017 Jun 14. doi: 10.1007/s00066-017-1161-6. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Taunk NK, Moraes FY, Escorcia FE, Mendez LC, Beal K, Marta GN.
External beam re-irradiation, combination chemoradiotherapy, and particle therapy for the treatment of recurrent glioblastoma.
Expert Rev Anticancer Ther. 2016;16(3):347-58. doi: 10.1586/14737140.2016.1143364. Epub 2016 Feb 9.
Source | Abstract | Full text | Similar articles



SECOND SURGERY



Kaloshi G, Petrela M.
Letter to the Editor. An extent of resection threshold for recurrent glioblastoma: why wait until recurrence?
J Neurosurg. 2017 Aug 18:1. doi: 10.3171/2017.6.JNS14868. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Montemurro N, Perrini P, Blanco MO, Vannozzi R.
Second surgery for recurrent glioblastoma: A concise overview of the current literature.
Clin Neurol Neurosurg. 2016 Mar;142:60-4. doi: 10.1016/j.clineuro.2016.01.010. Epub 2016 Jan 14.
Source | Abstract | Full text | Similar articles




Robin AM, Lee I, Kalkanis SN.
Reoperation for Recurrent Glioblastoma Multiforme.
Neurosurg Clin N Am. 2017 Jul;28(3):407-428. doi: 10.1016/j.nec.2017.02.007.
Source | Abstract | Full text | Similar articles



T CELL ACTIVATION AND PROLIFERATION



Carter T, Shaw H, Mulholland P.
Combining Ipilimumab and Bevacizumab in Glioblastoma: Is it Really Safe and Effective? Author Response.
Clin Oncol (R Coll Radiol). 2016 Jul 27. pii: S0936-6555(16)30187-X. doi: 10.1016/j.clon.2016.07.009. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Carter T, Shaw H, Cohn-Brown D, Chester K, Mulholland P.
Ipilimumab and Bevacizumab in Glioblastoma.
Clin Oncol (R Coll Radiol). 2016 May 8. pii: S0936-6555(16)30076-0. doi: 10.1016/j.clon.2016.04.042. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Tini P, Pirtoli L.
Combining Ipilimumab and Bevacizumab in Glioblastoma is Really Safe and Effective?
Clin Oncol (R Coll Radiol). 2016 Jun 18. pii: S0936-6555(16)30121-2. doi: 10.1016/j.clon.2016.06.003. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



TUMOR-TREATING FIELDS



Kesari S, Ram Z; EF-14 Trial Investigators.
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
CNS Oncol. 2017 Apr 12. doi: 10.2217/cns-2016-0049. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



VEGFR INHIBITORS



Cloughesy TF, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Ping J, Holland J, Weitzman R, Wen PY.
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.
Neuro Oncol. 2017 Oct 3. doi: 10.1093/neuonc/nox151. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Duerinck J, Du Four S, Bouttens F, Andre C, Verschaeve V, Van Fraeyenhove F, Chaskis C, D'Haene N, Le Mercier M, Rogiers A, Michotte A, Salmon I, Neyns B.
Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.
J Neurooncol. 2017 Oct 7. doi: 10.1007/s11060-017-2629-z. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Kalpathy-Cramer J, Chandra V, Da X, Ou Y, Emblem KE, Muzikansky A, Cai X, Douw L, Evans JG, Dietrich J, Chi AS, Wen PY, Stufflebeam S, Rosen B, Duda DG, Jain RK, Batchelor TT, Gerstner ER.
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.
J Neurooncol. 2016 Nov 16. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Cloughesy TF.
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.
Neuro Oncol. 2017 Aug 14. doi: 10.1093/neuonc/nox154. [Epub ahead of print]
Source | Abstract | Full text | Similar articles